Trial Profile
A Phase 1, Open-label, Randomized, Single-dose, Three-way Crossover Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Ciforadenant (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors Corvus Pharmaceuticals
- 26 Jan 2018 Status changed from active, no longer recruiting to completed.
- 07 Aug 2017 New trial record